Cullinan Therapeutics (CGEM) Share-based Compensation (2021 - 2023)
Historic Share-based Compensation for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to $7.5 million.
- Cullinan Therapeutics' Share-based Compensation rose 7.99% to $7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $30.4 million, marking a year-over-year increase of 887.43%. This contributed to the annual value of $37.8 million for FY2024, which is 2426.57% up from last year.
- According to the latest figures from Q4 2023, Cullinan Therapeutics' Share-based Compensation is $7.5 million, which was up 7.99% from $7.7 million recorded in Q3 2023.
- Over the past 5 years, Cullinan Therapeutics' Share-based Compensation peaked at $12.1 million during Q4 2021, and registered a low of $3.5 million during Q1 2021.
- Over the past 3 years, Cullinan Therapeutics' median Share-based Compensation value was $7.4 million (recorded in 2022), while the average stood at $6.9 million.
- Examining YoY changes over the last 5 years, Cullinan Therapeutics' Share-based Compensation showed a top increase of 10667.47% in 2022 and a maximum decrease of 3813.92% in 2022.
- Cullinan Therapeutics' Share-based Compensation (Quarter) stood at $12.1 million in 2021, then crashed by 38.14% to $7.5 million in 2022, then increased by 0.08% to $7.5 million in 2023.
- Its Share-based Compensation was $7.5 million in Q4 2023, compared to $7.7 million in Q3 2023 and $7.9 million in Q2 2023.